한글목차

개요

세계의 림프부종 치료 시장은 2023년에 11억 달러에 달하며, 2024-2031년의 예측 기간 중 CAGR 9.5%로 성장하며, 2031년에는 23억 달러에 달할 것으로 예측되고 있습니다.

림프부종은 일반적으로 신체의 림프계를 통해 배출되는 단백질이 많은 체액이 축적되어 조직이 부어오르는 것을 말합니다. 림프부종은 팔과 다리에 가장 많이 발생하지만 흉벽, 복부, 경부, 생식기에도 발생할 수 있습니다.

림프절은 림프계의 중요한 부분입니다. 림프부종은 림프절을 절제하거나 손상시키는 암 치료로 인해 발생할 수 있습니다. 림프액 배출을 방해하는 모든 유형의 문제가 림프부종을 유발할 수 있습니다.

림프부종 치료에는 일반적으로 물리치료와 림프부종의 영향을 받은 부위에서 체액을 이동시키는 의복과 붕대의 조합이 포함됩니다.

시장 역학 :

촉진요인

림프부종 치료를 위한 기술 발전 증가

세계 림프부종 시장 수요는 여러 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 의료 시스템의 기술 발전입니다. 림프부종은 만성적인 증상이며 일반적으로 림프액 배출 부족으로 인해 발생합니다.

주요 기업의 혁신적인 기술 발전은 시장 성장을 가속하고 있습니다. 이러한 효과적인 발전은 연구 발견을 새로운 치료법으로 전환하고 수백만 명의 림프 부종 환자의 치료를 개선하는 데 도움이 되었습니다. 예를 들어 2022년 10월 임페디메드(ImpediMed Limited)는 주요 암센터에서 림프부종이 유방암 환자에게 미치는 영향을 줄이기 위해 자사의 SOZO 디지털 건강 플랫폼의 사용을 확대한다고 발표했습니다.

또한 림프부종 치료에서 첨단 연구개발을 도입하고 새로운 치료법과 의약품을 출시하는 주요 업체들은 이 시장의 성장을 가속할 것으로 보입니다. 예를 들어 2023년 4월 AIROS Medical, Inc.는 미국 식품의약국(FDA)으로부터 새로운 연동식 공기압박 장비인 림프부종 치료용 트란칼가먼트의 판매 허가를 받았다고 발표했습니다.

또한 2022년 4월, 코야메디컬은 미국 식품의약국(FDA)의 승인을 받은 최초의 비공압식 능동적 압박 치료법인 데이스프링(Dayspring)의 미국 시판을 발표했습니다. 치료법입니다. 이와 같이 위의 요인들이 시장 성장을 촉진하고 있습니다.

억제요인

고가의 치료비, 줄기세포 치료에 따른 부작용, 제한된 치료 옵션, 개인의 인식 및 진단 부족 등의 요인이 시장 저해 요인으로 작용할 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 촉진요인
    • 림프부종 치료를 위한 기술 진보의 증가
    • 암이환율의 증가, 정부 구상과 자금 원조
  • 억제요인
    • 치료 방법의 고비용
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 미충족 요구
• 규제 분석
• 러시아·우크라이나 전쟁 영향 분석
• DMI의 견해

제6장 유형별

• 원발성 림프부종
• 연발성 림프부종

제7장 치료법

• Decongestive therapy
• 수술 요법
• 약물 요법
• 레이저 요법
• 기타

제8장 최종사용자별

• 병원 약국
• 소매 약국
• 온라인 약국
• 기타

제9장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제10장 경쟁 구도

• 경쟁 시나리오
• 제품 벤치마킹
• 기업 점유율 분석
• 주요 발전과 전략

제11장 기업 개요

• Kite Pharma
  • 회사 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Johnson and Johnson
• Sanofi S.A
• LGM Pharma
• Hubei Xunda Pharma
• Sigma Aldrich
• Midas Pharma
• Oishi Koseido Co. ltd
• Glentham Life Sciences
• Taro Pharmaceuticals

제12장 부록

영문목차

Overview

The global lymphedema treatment market reached US$ 1.1 billion in 2023 and is expected to reach US$ 2.3 billion by 2031 growing with a CAGR of 9.5% during the forecast period 2024-2031.

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of the lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any type of problem that blocks the drainage of lymph fluid can cause lymphedema.

Lymphedema treatment typically includes a combination of physical therapy and garments or bandaging that moves fluid from areas affected by lymphedema.

Market Dynamics: Drivers

Increasing Technological Advancements for Lymphedema Treatment

The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage.

The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema. For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.

Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth. For instance, in April 2023, AIROS Medical, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance to market a new peristaltic pneumatic compression device, truncal garments for lymphedema treatment.

Also, in April 2022, Koya Medical announced the U.S. commercial availability of its Dayspring active compression system for the treatment of lymphedema and venous diseases in the lower extremities. Dayspring is the first non-pneumatic active dynamic compression treatment cleared by the U.S. Food and Drug Administration (FDA). Thus, the above factors help to boost the market growth.

Restraints

Factors such as the high cost of the treatment procedure, side effects associated with stem cell therapy treatment, limited treatment options, and lack of awareness & diagnosis among individuals, are expected to hamper the market.

Segment Analysis

The global lymphedema treatment market is segmented based on type, treatment, end users, and region.

The decongestive therapy segment accounted for approximately 43.2% of the global lymphedema treatment market share

The decongestive therapy segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment therapy globally have contributed to the growing demand for lymphedema treatment. According to clinicalTrials.gov, in July 2022, Gulhane School of Medicine conducted a clinical trial on the Effect of Metabolic Syndrome on Complex Decongestive Physiotherapy Outcomes in Lymphedema Patients. The aim is to compare the effectiveness of complex decongestive physiotherapy (KBF) in patients with and without metabolic syndrome.

Moreover, key players in the industry research studies in the treatment of lymphedema would drive this segment growth. For instance, in July 2023, Cairo University conducted a clinical trial on the Effect Of Complete Decongestive Therapy on Carpal Tunnel Syndrome Post Upper Limb Lymphedema (CDT). The patients receives complete decongestive therapy in the form of intermittent pneumatic compression, exercising, bandaging, and manual lymphatic drainage. Thus, the above factors help to accelerate the market growth.

Also, in May 2022, PureTech Health announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels and observed improved tolerability of LYT-100. It is the potential treatment of conditions involving inflammation and fibrosis, including lung disease and disorders of lymphatic flow, such as lymphedema.

Geographical Analysis

North America accounted for approximately 41.2% of the global lymphedema treatment market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of lymphedema, and rising breast cancer, in the U.S., and Canada driving the market growth.

As per Lymphatic Education & Research Network in 2024, up to 250 million people worldwide have lymphedema (LE) with an estimated 10 million living with lymphedema (LE) in the United States, up to 30% of breast cancer survivors acquire debilitating LE.

Moreover, in this region, a major key player's partnerships & collaborations, well-advanced healthcare system, and new product launches would propel this market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema.

Also, in October 2022, ImpediMed announced the U.S. launch of a lymphedema prevention program with Genesis Care, a global organization dedicated to the care of cancer patients.

Similarly, in March 2024, NHLBI helps launch the first NIH National Commission on Lymphatic Diseases. The creation of this lymphatics commission is a gratifying and revolutionary step in this very important and relatively neglected field of research.

Market Segmentation

By Type

• Primary Lymphedema
• Secondary Lymphedema

By Treatment

• Stem Cell Therapy
• Decongestive therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

By End Users

• Hospital
• Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the lymphedema market include Kite Pharma, Johnson, and Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido Co. Ltd, Glentham Life Sciences, Taro Pharmaceuticals among others.

Key Developments

• In August 2023, Calamos Advisors LLC made a significant investment in Tactile Systems Technology, Inc. by acquiring 60,861 shares of the company's stock. The purchase amounted to approximately $999,000 and represented 0.26% ownership of Tactile Systems Technology. Tactile Systems Technology is a medical technology company dedicated to developing innovative devices for the treatment of conditions such as lymphedema, venous disorders, and pulmonary secretions retention.
• In June 2022, Hyperice, launched Normatec 3, the next evolution of the iconic Normatec series which uses dynamic air compression to advance everyday wellness and helps aid in faster recovery, and improved training. Normatec was developed to help people undergoing breast cancer treatment who often suffer from lymphedema caused by removal or damage to their lymph nodes.
• In May 2022, Hospice charity partners with AECC University College to provide new lymphoedema service. The initiative follows the success of Lewis-Manning Hospice Care's pilot mobile lymphoedema clinics by bringing its services closer to people's homes and making the service accessible and easy.

Why Purchase the Report?

• To visualize the global lymphedema treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lymphedema treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lymphedema treatment market report would provide approximately 69 tables, 70 figures, and 182 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End Users
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Technological Advancements for Lymphedema Treatment
    • 4.1.1.2. Increasing Prevalence of Cancer and Government Initiatives & Funding
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment Procedure
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Primary Lymphedema
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Secondary Lymphedema

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Decongestive therapy
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Surgery
• 7.4. Drug Therapy
• 7.5. Laser Therapy
• 7.6. Others

8. By End Users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 8.1.2. Market Attractiveness Index, By End Users
• 8.2. Hospital Pharmacy
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacy
• 8.4. Online Pharmacy
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Product Benchmarking
• 10.3. Company Share Analysis
• 10.4. Key Developments and Strategies

11. Company Profiles

• 11.1. Kite Pharma*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Johnson and Johnson
• 11.3. Sanofi S.A
• 11.4. LGM Pharma
• 11.5. Hubei Xunda Pharma
• 11.6. Sigma Aldrich
• 11.7. Midas Pharma
• 11.8. Oishi Koseido Co. ltd
• 11.9. Glentham Life Sciences
• 11.10. Taro Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us